JOHN VIERLING to Liver Cirrhosis
This is a "connection" page, showing publications JOHN VIERLING has written about Liver Cirrhosis.
Connection Strength
1.809
-
Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. Dig Dis Sci. 2018 03; 63(3):665-675.
Score: 0.385
-
Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2016 06; 14(6):903-906.e1.
Score: 0.332
-
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol. 2014 Aug; 61(2):200-9.
Score: 0.296
-
Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. Transl Res. 2018 05; 195:25-47.
Score: 0.095
-
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017 11; 2(11):814-823.
Score: 0.093
-
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016 May; 63(5):1493-505.
Score: 0.084
-
Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy. Dig Dis Sci. 2016 06; 61(6):1728-34.
Score: 0.084
-
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44.
Score: 0.080
-
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol. 2013 Mar; 58(3):479-87.
Score: 0.067
-
Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology. 2012 Aug; 56(2):464-73.
Score: 0.065
-
Management of patients with cirrhosis in Southern California: results of a practitioner survey. J Clin Gastroenterol. 2006 Feb; 40(2):156-61.
Score: 0.042
-
Future Treatment Options in PBC. Semin Liver Dis. 2005 Aug; 25(3):347-63.
Score: 0.040
-
Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol. 2004 Sep; 28(9):1204-11.
Score: 0.038
-
Overview of hepatitis B and transplantation in the hepatitis B patient. Semin Liver Dis. 2000; 20 Suppl 1:3-6.
Score: 0.027
-
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol. 2018 May; 53(5):679-688.
Score: 0.024
-
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 06 01; 376(22):2134-2146.
Score: 0.023
-
Hepatitis C virus is not recoverable from liver tissue in cryptogenic cirrhosis: failure to identify hepatitis C virus-RNA using reverse transcription-mediated polymerase chain reaction. Hum Pathol. 1996 Nov; 27(11):1161-5.
Score: 0.022
-
Limited role for CXC chemokines in the pathogenesis of alpha-naphthylisothiocyanate-induced liver injury. Am J Physiol Gastrointest Liver Physiol. 2004 Sep; 287(3):G734-41.
Score: 0.009